This looks like a win win spot with Myriad. The CEO in January said at the JPMorgsn conference that they were on schedule and had additional testing they would begin.
You've watched good companies go down when they met expectations in their quarterly earnings. QCOM, e.g., had a big share price run up prior to the release and 10Q and they plumeted from $48+ to $40-, when expectations were not gangbusters. That scenario has been repeated by others that met or beat estimates. I even heard an analyst say that if MSFT didn't beat the "whisper" number (well above guidance), they would go down.
So, here we have estimates quite high for MYGN, and share price super low, leading into the 10Q release. Low expectations for forward earnings. If they raise or reiterate guidance for the current quarter and for the year, I expect return to target share price. Maybe not $34 just yet, but $26+ to $29+ very soon.